Nemaura Medical (NASDAQ: NMRD) recently announced it would launch Miboko, its new metabolic health program, for employers and insurers. “The Miboko application, a service offering that has been in development over the past 18 months, uses a non-invasive glucose sensor … Continue reading →

NMRD appoints UK-based Dr. Arash Ghadar as Chief Operating Officer, brings decades of healthcare and technology experience Dr. Ghadar previously supervised product development lifecycles, feasibility studies, prototyping, validation, quality management, volume manufacturing, certification NMRD commercializing sugarBEAT(R) non-invasive, flexible, CGM device, … Continue reading →

Nemaura Medical (NASDAQ: NMRD) is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible and affordable continuous glucose monitoring (“CGM”) device. “As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT devices to MySugarWatch Limited, … Continue reading →

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently announced the rollout of its Miboko application by targeting insurers and employers In 2019, over $760 billion was spent on diabetes-related health care, … Continue reading →

Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS  Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and … Continue reading →

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of Miboko for employers and insurers. Miboko is a new metabolic health program … Continue reading →

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that its CEO Dr. Faz Chowdhury will present a corporate overview at the H.C. Wainwright … Continue reading →

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently completed the initial shipment of its sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, … Continue reading →

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs. Since its founding in 2011, Nemaura set out to develop a single platform technology to measure … Continue reading →

Nemaura Medical announced the successful completion of its initial shipment of sugarBEAT(R) continuous glucose monitor devices to its UK licensee The initial shipment, which comprised 5,000 CGM devices and 200,000 sensors, is expected to result in follow-on monthly orders of … Continue reading →